Chromocell Therapeutics (CHRO) announced the unveiling of its injectable depot program utilizing peripheral nerve blocks for the treatment of post-operative pain. The depot program is based on the Company’s novel NaV1.7 molecule for treating chronic pain and eye pain. “We are leveraging our existing know-how and intellectual property to target different pain indications and methods of delivery in an efficient and synergistic manner. We are taking advantage of the extensive pre-clinical and Phase I studies performed with CC8464 demonstrating strong efficacy in a wide variety of preclinical models and no dose limiting tolerability concerns in four Phase I trials,” said Frank Knuettel, Chief Executive Officer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CHRO:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
